Biosimilar Value
Patient support services and
Patient support services and
programs to assist with access
Biosimilar Reimbursement
Biosimilar reimbursement has evolved significantly since the launch of the first biosimilar in the U.S.
Centers for Medicare & Medicaid Services (CMS) has adjusted policy in order to ensure providers are not disadvantaged when utilizing biosimilars.
- Each biosimilar has its own unique HCPCS code
- When the reimbursement rate is based on ASP, the 6% add-on for biosimilars is based on the reference products' ASP
